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Therefore, we investigated oxidative stress levels in AMI patients
with lipophilic atorvastatin or hydrophilic pravastatin. Methods and
results: The study population included a prospective, randomized,
open-label, study in AMI patients within ALPS-AMI study. Patients that
have undergone successful percutaneous coronary intervention will be
randomly allocated to receive either atorvastatin or pravastatin with the
treatment goal of lowering their low-density lipoprotein-cholesterol
level below 100mg/dl for 2 years. Diacron-reactive oxygen metabolite
(dROM) and biological antioxidant potential (BAP) levelsweremeasured
in AMI patients with lipophilic (atorvastatin, n = 38) and hydrophilic
(pravastatin, n = 36) statin therapy on admission (dROM: 395.5 ± 37.5
vs. 392.1 ± 35.6 Carratelli units (U. Carr) (p= 0.37), BAP: 2756.3 ± 75.2
vs. 2849.1 ± 71.6 mmol/l (p = 0.39), respectively) and 6, 12, and
24 months (24 months: dROM: 374.5 ± 41.5 vs. 381.1 ± 37.6 U. Carr
(p= 0.28), BAP: 2957.3 ± 135.9 vs. 2941.5 ± 121.3 mmol/l (p= 0.48),
respectively). Conclusion: This is the ﬁrst clinical trial to compare the
effects of lipophilic and hydrophilic statin therapy on oxidative stress
levels and no difference was noted in oxidative stress levels between
lipophilic and hydrophilic statin therapy in patients with AMI during the
follow-up period.
doi:10.1016/j.lfs.2014.01.050
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Obesity is associated with higher risk of premature death due to
metabolic and cardiovascular abnormalities. One third of obese
individuals, however, have a “metabolically healthy” phenotype and it
is debated whether this status carries lower cardiovascular risk than its
metabolically unhealthy counterpart. Given the role of the endothelin
(ET)-1 system in the development of obesity-related vascular dysfunc-
tion, we investigated whether differences exist in ET-1-dependent
vasoconstrictor activity between the divergent obesity subphenotypes.
To this end, we compared vasodilator responses (strain-gauge plethys-
mography) to intra-arterial infusion of the selective ETA receptor
blocker BQ-123 (10 nmol/min for 60 min) in healthy subjects (n = 31)
and obese patients (n= 38); obese patients were divided in two
subgroups according to the absence (n= 11) or presence (n= 27) of
any of the glucose or lipid abnormalities characteristic of the metabolic
syndrome (MetS; ATP III criteria). The vasodilator response to BQ-123
was greater in obese than in lean subjects (P b 0.001), whereas no
difference was observed in the response to BQ-123 between metabol-
ically healthy and unhealthy obese patients (P N 0.05). Similarly, BQ-
123-induced vasodilation was related to the number of MetS compo-
nent in the whole population (P = 0.008), but not within the obese
group (P N 0.05). In the whole population, body mass index and mean
arterial pressure were signiﬁcant determinants of the response to BQ-
123 (r = 0.46 and r = 0.42, respectively; both P b 0.001), whereas no
correlation was observed between BQ-123-induced vasodilation and
either plasma glucose, triglycerides or HDL-cholesterol levels (all
P N 0.05). In conclusion, ET-1-dependent vasoconstrictor tone is higher
in obese patients than in their lean counterpart, but this defect is not
inﬂuenced by the presence of obesity-related metabolic abnormalities.
doi:10.1016/j.lfs.2014.01.051
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There is a growing body of evidence suggested that epigallocate-
chin gallate (EGCG), a major catechin isolated from green tea, has
several beneﬁcial effects such as anti-oxidant and anti-inﬂammatory
activities. However, whether treatment with EGCG could suppress the
ET-1-induced contraction in large arteries from type 2 diabetic rats is
unknown. We hypothesized that long-term treatment with EGCG
would attenuate the ET-1-induced contractions in type 2 diabetic
arteries. To test this hypothesis, Otsuka Long–Evans Tokushima fatty
(OLETF) rats (43 weeks old)were treatedwith EGCG (200 mg/kg/day for
2 months, p.o.) and contractile/relaxant responses to ET-1, phenyleph-
rine (PE), acetylcholine (ACh) and sodium nitroprusside (SNP) in the
presence and absence of endotheliumweremeasured in common carotid
artery (CA) and thoracic aorta (TA) from EGCG-treated and -untreated
OLETF rats and control Long–Evans Tokushima Otsuka (LETO) rats. In
OLETF rats, EGCG attenuated sensitivity to ET-1 in CA [pD2, EGCG-
treated: 7.95 ± 0.07 vs. -untreated: 8.15 ± 0.06 (p b 0.05)] and TA [pD2,
EGCG-treated: 7.98 ± 0.08 vs. -untreated: 8.24 ± 0.06 (p b 0.05)] com-
pared to untreated groups. However, EGCG did not alter PE-induced
contractions in both arteries from OLETF rats. In the endothelium-
denuded arteries, EGCG did not affect ET-1- and PE-induced contractions
in both OLETF and LETO groups. ACh-induced relaxations were increased
by EGCG treatment in CA and TA from OLETF group. SNP-induced
relaxations were similar between EGCG-treated and -untreated groups.
Our data suggest that within the timescale investigated here, EGCG
attenuates ET-1-induced contractions in large arteries from type 2
diabetic rats and one of the mechanisms may be attributable to
normalizing endothelial function.
doi:10.1016/j.lfs.2014.01.052
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Background and objective: Previous studies have described an
association between kidney diseases and endothelin. Primary ne-
phrotic syndrome (NS) is the common renal disease in children. The
aim of this study was to determine whether polymorphisms in the
endothelin-A receptor gene might be associated with the morbidity
and the steroid response of primary nephrotic syndrome in children.
Methods: 53 children with primary nephrotic syndrome as case group
were subdivided into steroid resistance NS group and non-steroid
resistance NS group; hypertension group and non-hypertension
group. 50 healthy children were as control group. All subjects were
genotyped for endothelin-A receptor polymorphisms in locus
rs10305936 (in exon 8 of the EDNRA) by using the polymerase chain
reaction and direct gene sequence test technique. Results: (1) There is
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